MEDB-71. Molecular characterisation of group 4 medulloblastoma improves risk-stratification and its biological understanding

Group 4 (MB(Grp4)) accounts for ~40% of medulloblastoma and the majority of non-WNT/non-SHH cases, yet its underpinning biology is poorly understood, and survival outcomes are not sufficiently explained by established clinico-pathological risk factors. We investigated the clinical and molecular corr...

Descripción completa

Detalles Bibliográficos
Autores principales: Goddard, Jack, Castle, Jemma, Southworth, Emily, Fletcher, Anya, Crosier, Stephen, Martin-Guerrero, Idoia, Garcia-Ariza, Miguel, Navajas, Aurora, Masliah-Planchon, Julien, Bourdeaut, Franck, Dufour, Christelle, Goschizk, Tobias, Pietsch, Torsten, Richardson, Stacey, Hill, Rebecca M, Williamson, Daniel, Bailey, Simon, Schwalbe, Edward C, Clifford, Steven C, Hicks, Debbie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Medulloblastoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165305/
http://dx.doi.org/10.1093/neuonc/noac079.445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165305/
http://dx.doi.org/10.1093/neuonc/noac079.445

Ejemplares similares